von Matthiessen H, Koldovsky U, Feldhammer B
Dtsch Med Wochenschr. 1980 Oct 10;105(41):1424-7.
The effect of medroxyprogesterone acetate, oestradiol-17 beta and testolactone on 3H-thymidine incorporation in human mammary carcinoma was studied in vitro. 54% of the tumours reacted to medroxyprogesterone, while testolactone and oestradiol-17 beta changed 3H-thymidine incorporation in 45.1 and 41.3%, respectively. Both inhibition and the in vivo undesirable stimulation of 3H-thymidine incorporation was observed. No relation could be established between oestrogen receptor content and reaction of the mammary carcinoma to oestradiol-17 beta. On the other hand, the gestagen receptor content and the reaction of the mammary carcinoma to medroxyprogesterone acetate correlated significantly (P < 0.001). This underlines the increasing significance of the gestagen receptor in the selective endocrine treatment of mammary carcinoma.
在体外研究了醋酸甲羟孕酮、17β-雌二醇和睾酮内酯对人乳腺癌中3H-胸腺嘧啶核苷掺入的影响。54%的肿瘤对醋酸甲羟孕酮有反应,而睾酮内酯和17β-雌二醇分别使3H-胸腺嘧啶核苷掺入改变了45.1%和41.3%。观察到3H-胸腺嘧啶核苷掺入既有抑制作用,也有体内不良刺激作用。雌激素受体含量与乳腺癌对17β-雌二醇的反应之间未发现相关性。另一方面,孕激素受体含量与乳腺癌对醋酸甲羟孕酮的反应显著相关(P<0.001)。这突出了孕激素受体在乳腺癌选择性内分泌治疗中的重要性日益增加。